VK Gadi, MD, PhD

VK Gadi, MD, PhD, is deputy director of the University of Illinois (UI) Cancer Center and a medical oncologist at UI Health, as well as an assistant professor of clinical medicine and director of Medical Oncology in the Division of Hematology and Oncology at the UI College of Medicine in Chicago

Articles by VK Gadi, MD, PhD

Selecting and Sequencing Therapy in Patients with HER2+ mBC and CNS Metastases

ByVK Gadi, MD, PhD

July 1st 2022

An expert oncologist reviews key considerations in selecting and sequencing treatment appropriately in patients with HER2+ breast cancer and CNS metastases, including challenges associated with treating leptomeningeal disease.

Evolving Approaches in the First- and Second-Line Treatment of HER2+ mBC

ByVK Gadi, MD, PhD

July 1st 2022

Vijayakrishna Gadi, MD, PhD, discusses factors to consider in the first- and second-line management of HER2+ mBC with particular emphasis on treatment selection, safety, and sequencing.

HER2 Dual Blockade in Early Stage HER2+ Breast Cancer

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

June 27th 2022

Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.

Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

ByAndrew D. Seidman, MD,VK Gadi, MD, PhD,Tiffany A. Traina, MD,William J. Gradishar, MD,Stephanie L. Graff, MD, FACP

June 27th 2022

Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.

Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

March 10th 2022

Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.

Treatment Options for HER2+, ER+ Metastatic Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

March 2nd 2022

A panel of experts briefly reviews the treatment options available for patients with ER+, HER2+ metastatic breast cancer.

Special HER2+ mBC Populations: HR+ or HER2-Low Patients

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

March 2nd 2022

Expert panelists discuss the optimal management patients with special subsets of HER2+ metastatic breast cancer, such as HR+ or HER2-low disease.

Potential Role of Surgery in HER2+ Metastatic Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 23rd 2022

Shared insight on the potential role for surgery in the setting of HER2+ metastatic breast cancer in the context of pharmacologic therapy.

SABCS 2021: Small Molecule Clinical Trials in R/R HER2+ mBC

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 23rd 2022

Rounding out their conversation on SABCS 2021, experts discuss small molecule–based treatment strategies for relapsed/refractory HER2+ metastatic breast cancer.

SABCS 2021: Combination Strategies Under Investigation for R/R HER2+ mBC

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 16th 2022

Considering data from the SABCS 2021 annual meeting, experts discuss novel combination strategies for relapsed/refractory HER2+ metastatic breast cancer.

HER2+ Breast Cancer: Updates on HER2CLIMB and CNS Disease Management

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 16th 2022

A brief review of updated data from HER2CLIMB and discussion on which agents may be best for treating patients with CNS disease.

Novel Treatment Approaches to R/R HER2+ Metastatic Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 9th 2022

Experts discuss the role of novel therapies in relapsed/refractory HER2+ metastatic breast cancer accounting for results from recent clinical trial.

HER2+ mBC: Impact of T-DM1 and T-DXd Beyond the Frontline Setting

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 9th 2022

Shared insight on the roles of trastuzumab emtansine and trastuzumab deruxtecan in relapsed/refractory HER2+ metastatic breast cancer.

Monitoring Patients With HER2+ Metastatic Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 2nd 2022

A brief review of patient monitoring and screening practices in the setting of HER2+ metastatic breast cancer.

Patient Case: Frontline Treatment Options for HER2+ mBC

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

February 2nd 2022

Taking into account a patient case of HER2+ metastatic breast cancer, experts review current frontline treatment options.

Patient Case: Biomarker Testing in Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

January 26th 2022

Centered on a patient presentation of breast cancer, panelists consider optimal biomarker testing strategies to inform their treatment approach.

An Overview on the Current State of Metastatic Breast Cancer

ByVK Gadi, MD, PhD,Charles Geyer, MD, FACP,Nancy Lin, MD,Michelle Melisko, MD

January 26th 2022

Expert perspectives on the current treatment landscape of metastatic breast cancer and the unmet needs prevalent across various subsets of disease.

VK Gadi, MD, PhD

Articles by VK Gadi, MD, PhD

Selecting and Sequencing Therapy in Patients with HER2+ mBC and CNS Metastases

Evolving Approaches in the First- and Second-Line Treatment of HER2+ mBC

HER2 Dual Blockade in Early Stage HER2+ Breast Cancer

Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

Treatment Options for HER2+, ER+ Metastatic Breast Cancer

Special HER2+ mBC Populations: HR+ or HER2-Low Patients

Potential Role of Surgery in HER2+ Metastatic Breast Cancer

SABCS 2021: Small Molecule Clinical Trials in R/R HER2+ mBC

SABCS 2021: Combination Strategies Under Investigation for R/R HER2+ mBC

HER2+ Breast Cancer: Updates on HER2CLIMB and CNS Disease Management

Novel Treatment Approaches to R/R HER2+ Metastatic Breast Cancer

HER2+ mBC: Impact of T-DM1 and T-DXd Beyond the Frontline Setting

Monitoring Patients With HER2+ Metastatic Breast Cancer

Patient Case: Frontline Treatment Options for HER2+ mBC

Patient Case: Biomarker Testing in Breast Cancer

An Overview on the Current State of Metastatic Breast Cancer

Trending on OncLive

FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies

As ADC Options Expand, Sequencing and Toxicity Management Become the Next Challenges in Gynecologic Oncology

Epcoritamab Plus Lenalidomide Improves PFS vs R-GemOx in R/R DLBCL

MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL

Experts Outline the Evolving Role of ctDNA-Based MRD Testing Across Solid Tumors